tetano
Editor, Senior Moderator
Clin Transl Immunology
. 2021 Mar 18;10(3):e1240.
doi: 10.1002/cti2.1240. eCollection 2021.
RGD-binding integrins and TGF-? in SARS-CoV-2 infections - novel targets to treat COVID-19 patients?
Ingrid Carvacho[SUP] 1 [/SUP], Matthias Piesche[SUP] 2 3 [/SUP]
Affiliations
Abstract
The new coronavirus SARS-CoV-2 is a global pandemic and a severe public health crisis. SARS-CoV-2 is highly contagious and shows high mortality rates, especially in elderly and patients with pre-existing medical conditions. At the current stage, no effective drugs are available to treat these patients. In this review, we analyse the rationale of targeting RGD-binding integrins to potentially inhibit viral cell infection and to block TGF-? activation, which is involved in the severity of several human pathologies, including the complications of severe COVID-19 cases. Furthermore, we demonstrate the correlation between ACE2 and TGF-? expression and the possible consequences for severe COVID-19 infections. Finally, we list approved drugs or drugs in clinical trials for other diseases that also target the RGD-binding integrins or TGF-?. These drugs have already shown a good safety profile and, therefore, can be faster brought into a trial to treat COVID-19 patients.
Keywords: ARDS; COVID?19; RGD?binding integrins; TGF??; cytokines; inflammation.
. 2021 Mar 18;10(3):e1240.
doi: 10.1002/cti2.1240. eCollection 2021.
RGD-binding integrins and TGF-? in SARS-CoV-2 infections - novel targets to treat COVID-19 patients?
Ingrid Carvacho[SUP] 1 [/SUP], Matthias Piesche[SUP] 2 3 [/SUP]
Affiliations
- PMID: 33747508
- PMCID: PMC7971943
- DOI: 10.1002/cti2.1240
Abstract
The new coronavirus SARS-CoV-2 is a global pandemic and a severe public health crisis. SARS-CoV-2 is highly contagious and shows high mortality rates, especially in elderly and patients with pre-existing medical conditions. At the current stage, no effective drugs are available to treat these patients. In this review, we analyse the rationale of targeting RGD-binding integrins to potentially inhibit viral cell infection and to block TGF-? activation, which is involved in the severity of several human pathologies, including the complications of severe COVID-19 cases. Furthermore, we demonstrate the correlation between ACE2 and TGF-? expression and the possible consequences for severe COVID-19 infections. Finally, we list approved drugs or drugs in clinical trials for other diseases that also target the RGD-binding integrins or TGF-?. These drugs have already shown a good safety profile and, therefore, can be faster brought into a trial to treat COVID-19 patients.
Keywords: ARDS; COVID?19; RGD?binding integrins; TGF??; cytokines; inflammation.